- Trials with a EudraCT protocol (1,979)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1,979 result(s) found for: Adenocarcinoma.
Displaying page 17 of 99.
EudraCT Number: 2011-004923-11 | Sponsor Protocol Number: 20070622 | Start Date*: 2012-12-11 | ||||||||||||||||||||||||||
Sponsor Name:Amgen Inc | ||||||||||||||||||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG 102) with Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive... | ||||||||||||||||||||||||||||
Medical condition: Advanced MET-Positive Gastric, Lower Esophageal or Gastroesophageal Junction Adenocarcinoma | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GR (Completed) IT (Completed) CZ (Completed) BE (Completed) PT (Completed) AT (Completed) GB (Completed) DE (Completed) SE (Completed) HU (Completed) ES (Completed) DK (Prematurely Ended) BG (Completed) PL (Completed) SK (Prematurely Ended) RO (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-001518-34 | Sponsor Protocol Number: ML20296 | Start Date*: 2006-07-17 |
Sponsor Name:Roche Farma, S.A. | ||
Full Title: Estudio fase II abierto, no aleatorizado, de erlotinib en combinación con gemcitabina en pacientes con adenocarcinoma de páncreas avanzado irresecable o metastásico: relación entre rash cutáneo y ... | ||
Medical condition: Adenocarcinoma de páncreas avanzado irresecable o metastásico [Advanced unresectable or metastatic adenocarcinoma of the pancreas]. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-002909-25 | Sponsor Protocol Number: 74310 | Start Date*: 2020-10-21 |
Sponsor Name:Amsterdam University Medical Centers | ||
Full Title: Blood-borne assessment of stromal activation in esophageal adenocarcinoma to guide tocilizumab therapy: a randomized phase II proof-of-concept study | ||
Medical condition: oesophageal adenocarcinoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000050-22 | Sponsor Protocol Number: SEGCG18-01 | Start Date*: 2018-04-24 | |||||||||||
Sponsor Name:Skåne University Hospital, Department of Oncology | |||||||||||||
Full Title: Irinotecan-based triplet (FOLFOXIRI) as perioperative treatment in resectable gastric and gastroesophageal junction adenocarcinoma. | |||||||||||||
Medical condition: Resectabel gastric and gastroesophageal junction adenocarcinoma. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001314-25 | Sponsor Protocol Number: PEMBRACA | Start Date*: 2018-10-12 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA | |||||||||||||
Full Title: A phase II study of Pembrolizumab plus Carboplatin in BRCA-related metastatic breast cancer | |||||||||||||
Medical condition: BRCA-related metastatic breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003838-15 | Sponsor Protocol Number: 82/2006/O/Sper | Start Date*: 2006-09-12 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | |||||||||||||
Full Title: CETUXIMAB IN COMBINATION WITH CISPLATIN PLUS DOCETAXEL TO EVALUATE THE ACTIVITY AND SAFETY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC GASTRIC AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA: PHAS... | |||||||||||||
Medical condition: Advanced or metastatic gastric and gastroesophageal junction adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003048-22 | Sponsor Protocol Number: Uni-Koeln-3571 | Start Date*: 2020-06-16 | |||||||||||
Sponsor Name:Universität zu Köln | |||||||||||||
Full Title: A phase II trial to evaluate safety and efficacy of adding durvalumab (MEDI4736) to standard neoadjuvant radiochemotherapy and of adjuvant durvalumab +/- tremelimumab in locally advanced esophageal... | |||||||||||||
Medical condition: locally advanced esophageal adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004792-30 | Sponsor Protocol Number: HE316 | Start Date*: 2018-10-03 | |||||||||||
Sponsor Name:Hellenic Cooperative Oncology Group (HeCOG) | |||||||||||||
Full Title: Phase Ib-II study of Ramucirumab combined with standard Nab-paclitaxel and Gemcitabine as first-line treatment in patients with advanced pancreatic adenocarcinoma | |||||||||||||
Medical condition: Advanced pancreatic adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003080-26 | Sponsor Protocol Number: CASSANDRA | Start Date*: 2020-10-14 | |||||||||||
Sponsor Name:FONDAZIONE GISCAD (GRUPPO ITALIANO PER LO STUDIO DEI CARCINOMI DELL'APPARATO DIGERENTE) | |||||||||||||
Full Title: A randomized phase II trial of short-course versus long-course pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma (PDAC). | |||||||||||||
Medical condition: Patients with pancreatic ductal adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005696-24 | Sponsor Protocol Number: MS200095-0022 | Start Date*: 2016-07-04 |
Sponsor Name:Merck KGaA | ||
Full Title: A Phase II, single-arm trial to investigate tepotinib in advanced (locally advanced or metastatic) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (V... | ||
Medical condition: Advanced (stage IIIB/IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Trial now transitioned) DE (Trial now transitioned) ES (Trial now transitioned) FR (Trial now transitioned) AT (Completed) NL (Trial now transitioned) IT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2011-002331-25 | Sponsor Protocol Number: BP27836 | Start Date*: 2011-12-07 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: An Open-Label, Randomized, Multicenter Phase IIa Study Evaluating Pertuzumab in Combination with Trastuzumab and Chemotherapy in Patients with HER2-Positive Advanced Gastric Cancer | |||||||||||||
Medical condition: HER2-positive adenocarcinoma of the stomach or gastroesophageal junction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) BE (Completed) CZ (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001495-38 | Sponsor Protocol Number: XYN-602 | Start Date*: 2019-02-05 | ||||||||||||||||
Sponsor Name:Xynomic Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Randomized, Phase 3, Double-blind, Placebo-controlled Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma | ||||||||||||||||||
Medical condition: Locally Advanced or Metastatic Renal Cell Carcinoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005648-25 | Sponsor Protocol Number: PHRC/07-03/RENNES | Start Date*: 2008-01-31 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:C.H.U. de RENNES | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Carcinome rénal à cellules claires (CRCC) traité par molécules antiangiogéniques en situation adjuvante: valeur pronostique et thérapeutique des altérations du gène VHL et de l’expression plasmatiq... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Carcinome rénal à cellules claires (CRCC) traité par molécules antiangiogéniques en situation adjuvante | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: FR (Ongoing) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002773-38 | Sponsor Protocol Number: AIO-KRK-0214 | Start Date*: 2016-12-20 | |||||||||||||||||||||
Sponsor Name:AIO-Studien-gGmbH | |||||||||||||||||||||||
Full Title: mFOLFOX6 vs. mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial | |||||||||||||||||||||||
Medical condition: Patients with locally advanced rectal or rectosigmoid cancer staged cT3 CRM-negative with MRI | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) AT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-004572-34 | Sponsor Protocol Number: MM-141-07-02-02 | Start Date*: 2016-09-16 | |||||||||||
Sponsor Name:Merrimack Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 plus Nab-paclitaxel and Gemcitabine versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer | |||||||||||||
Medical condition: Patients with metastatic adenocarcinoma of the pancreas who have not received prior therapy for their metastatic disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) BE (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001066-42 | Sponsor Protocol Number: GETNE-T1812 | Start Date*: 2020-02-20 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Spanish Group of Neuroendocrine Tumors (GETNE) | |||||||||||||||||||||||||||||||||||||||||||
Full Title: A phase II study of durvalumab (MEDI4736) plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma - The DUTHY trial | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Advanced, radioiodine-refractory differentiated thyroid carcinoma, including papillary, follicular, Hürtle Cell and poorly-differentiated thyroid carcinoma (DTC). Advanced medullary thyroid carcino... | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002269-47 | Sponsor Protocol Number: STH18441 | Start Date*: 2015-12-02 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust | ||||||||||||||||||||||||||||||||||||||
Full Title: Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy. | ||||||||||||||||||||||||||||||||||||||
Medical condition: Iodine-refractory thyroid cancer of papillary, follicular, Hürthle cell or poorly differentiated carcinoma | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000742-21 | Sponsor Protocol Number: 2017/2527 | Start Date*: 2017-07-31 | |||||||||||||||||||||
Sponsor Name:Gustave Roussy | |||||||||||||||||||||||
Full Title: Efficacy of a selective MEK (trametinib) and BRAFV600E (dabrafenib) inhibitors associated with radioactive iodine (RAI) for the treatment of refractory metastatic differentiated thyroid cancer with... | |||||||||||||||||||||||
Medical condition: Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients with RAS or BRAF mutation | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002419-48 | Sponsor Protocol Number: GETNE-T2216 | Start Date*: 2023-03-27 | |||||||||||||||||||||
Sponsor Name:Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE) | |||||||||||||||||||||||
Full Title: Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer. | |||||||||||||||||||||||
Medical condition: Patients with radioiodine-refractory differentiated thyroid cancer (DTC). | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004559-34 | Sponsor Protocol Number: DS8201-A-U306 | Start Date*: 2021-07-01 | |||||||||||
Sponsor Name:Daiichi Sankyo, Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, 2-Arm Randomized, Open-Label Study of Trastuzumab Deruxtecan in Subjects with HER2 Positive Metastatic and/or Unresectable Gastric or Gastro Esophageal Junction (GEJ) Adenoc... | |||||||||||||
Medical condition: HER2 Positive Metastatic and/or Unresectable Gastric or Gastro Esophageal Junction (GEJ)Adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) IE (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
